Amicus Therapeutics Receives Marketing Authorization for Galafold® (migalastat) for Fabry Disease in Argentina

NEXT STORY
Harrow Health Forms Stowe Pharmaceuticals Subsidiary to Develop Broad Spectrum Anti-Microbial Ophthalmic and Otic Therapeutics
PREV STORY
Hemispherx Secures Corrections from Two Stock News Organizations Related to Their Inaccurate Reporting of an Equity Distribution Agreement Disclosed in a Recent SEC Filing
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Cellceutix Provides Update on Developing p53 Drug Candidate Kevetrin as an Oral Anti-Cancer Agent

BEVERLY, Mass., March 03, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), a ...

author_avatar
NASDAQ Market News

Replimune Appoints Dieter Weinand as Chairman and Paolo Pucci to the Board of Directors

author_avatar
NASDAQ Market News

Aptose to Release Fourth Quarter and Year End December 31, 2019 Financial Results and Hold Conference Call on March 10, 2020

author_avatar
NASDAQ Market News